Literature DB >> 35332416

MicroRNAs in hypertrophic cardiomyopathy: pathogenesis, diagnosis, treatment potential and roles as clinical biomarkers.

Fanyan Luo1,2, Wei Liu1,2, Haisong Bu3,4.   

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common heritable cardiomyopathy and is characterized by increased left ventricular wall thickness, but existing diagnostic and treatment approaches face limitations. MicroRNAs (miRNAs) are type of noncoding RNA molecule that plays crucial roles in the pathological process of cardiac remodelling. Accordingly, miRNAs related to HCM may represent potential novel therapeutic targets. In this review, we first discuss the different roles of miRNAs in the development of HCM. We then summarize the roles of common miRNAs as diagnostic and clinical biomarkers in HCM. Finally, we outline current and future challenges and potential new directions for miRNA-based therapeutics for HCM.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biomarkers; Diagnosis; Hypertrophic cardiomyopathy; MicroRNAs; Pathogenesis; Treatment

Mesh：

Substances：

Year:  2022        PMID： 35332416     DOI： 10.1007/s10741-022-10231-z

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN： 1382-4147            Impact factor:   4.654


  79 in total

1.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

2.  Clinical Course and Management of Hypertrophic Cardiomyopathy.

Authors:  Barry J Maron
Journal:  N Engl J Med       Date:  2018-11-15       Impact factor: 91.245

3.  Prognostic value of serial measurements of highly sensitive cardiac troponin I in stable outpatients with nonischemic chronic heart failure.

Authors:  Chiho Kawahara; Takayoshi Tsutamoto; Hiroshi Sakai; Keizo Nishiyama; Masayuki Yamaji; Masanori Fujii; Takashi Yamamoto; Minoru Horie
Journal:  Am Heart J       Date:  2011-09-15       Impact factor: 4.749

Review 4.  Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine.

Authors:  Barry J Maron; Steve R Ommen; Christopher Semsarian; Paolo Spirito; Iacopo Olivotto; Martin S Maron
Journal:  J Am Coll Cardiol       Date:  2014-07-08       Impact factor: 24.094

Review 5.  New perspectives on the prevalence of hypertrophic cardiomyopathy.

Authors:  Christopher Semsarian; Jodie Ingles; Martin S Maron; Barry J Maron
Journal:  J Am Coll Cardiol       Date:  2015-03-31       Impact factor: 24.094

6.  MiRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art.

Authors:  Andreas Angelopoulos; Evangelos Oikonomou; Georgia Vogiatzi; Alexios Antonopoulos; Sotirios Tsalamandris; Christos Georgakopoulos; Paraskevi Papanikolaou; George Lazaros; Georgios Charalambous; Gerasimos Siasos; Charalambos Vlachopoulos; Dimitris Tousoulis
Journal:  Curr Med Chem       Date:  2021-04-05       Impact factor: 4.530

Review 7.  MicroRNA regulatory networks in cardiovascular development.

Authors:  Ning Liu; Eric N Olson
Journal:  Dev Cell       Date:  2010-04-20       Impact factor: 12.270

Review 8.  Pervasive roles of microRNAs in cardiovascular biology.

Authors:  Eric M Small; Eric N Olson
Journal:  Nature       Date:  2011-01-20       Impact factor: 49.962

9.  B-type natriuretic peptide and survival in hypertrophic cardiomyopathy.

Authors:  Jeffrey B Geske; Paul M McKie; Steve R Ommen; Paul Sorajja
Journal:  J Am Coll Cardiol       Date:  2013-04-16       Impact factor: 24.094

Review 10.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Authors:  Steve R Ommen; Seema Mital; Michael A Burke; Sharlene M Day; Anita Deswal; Perry Elliott; Lauren L Evanovich; Judy Hung; José A Joglar; Paul Kantor; Carey Kimmelstiel; Michelle Kittleson; Mark S Link; Martin S Maron; Matthew W Martinez; Christina Y Miyake; Hartzell V Schaff; Christopher Semsarian; Paul Sorajja
Journal:  Circulation       Date:  2020-11-20       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.